the Center for Drug Evaluation and Research (CDER) and the Center for Devices and Radiological Health (CDRH).

Documentation expectations at this juncture include:

• Documentation that clearly states the product’s classification.
• A detailed description of how the drug and device components work together.

While involving multiple FDA centers, it is important to coordinate between them. Failure to do so could lead to misclassifications or mismanaged timelines. Consultation with the FDA Office of Combination Products (OCP) may provide additional clarity and guidance.

Step 2: Pre-Submission Activities and Guidance Requests

Once the classification is determined, engaging in pre-submission activities is a critical next step. Pre-submission activities involve developing a robust framework around your product’s regulatory strategy and gathering insights from the FDA.

Requesting formal Guidance from the FDA can help delineate the data requirements for your auto-injector. The following actions are recommended:

• Contact FDA OCP: Initiate contact with the OCP for guidance on regulatory pathways, identifying the appropriate submission type, such as a 510(k), PMA, NDA, or BLA.
• Pre-Submission Meeting: Schedule a pre-submission meeting to discuss clinical data requirements, labeling needs, and any potential challenges. This meeting can provide invaluable insights into what reviewers will expect.
• Prepare a Pre-Submission Package: Outline detailed aspects of the combination product, including a proposed study design, relevant protocols, and a plan for post-market surveillance.

Documentation at this stage includes:

• A summary of product description and intended use.
• Proposed regulatory submission strategy.

Obtaining feedback from the FDA can save significant time and resources, preventing unexpected regulatory hurdles later in the development process. Use the feedback received to refine your development strategy and ensure compliance with relevant guidelines.

Step 3: Development and Validation of the Auto-Injector

Following pre-submission activities, the next step involves the development and validation of your auto-injector device. This phase is pivotal for ensuring that your combination product meets FDA requirements prior to regulatory submission.

Key activities during the development and validation phase include:

• Design Controls: Implement design controls as mandated by ISO 13485 to ensure quality and consistency. This includes climate control, sterility, functionality, and safety evaluations.
• Human Factors Studies: Conduct human factors studies to demonstrate usability and ensure that patients can effectively use the auto-injector. These studies can mitigate risks associated with incorrect usage.
• Stability Testing: Perform stability testing for drug components according to ICH guidelines to establish product expiration dating and storage conditions.

Documentation expectations during this phase focus on:

• Design and development reports reflecting compliance with FDA design control standards.
• Reports from human factors studies and usability testing.
• Stability study reports outlining testing parameters and results.

All data collected must be statistically valid and exquisitely documented, as they form the basis of your subsequent regulatory submission.

Step 4: Preparing the Regulatory Submission Dossier

The preparation of the regulatory submission dossier is an intensive step, requiring diligent compilation of all documentation, data, and evidence gathered through the development process. Depending on the classification of the auto-injector, you may prepare for a 510(k), PMA, NDA, or BLA submission.

A comprehensive dossier typically includes:

• Quality and Chemistry, Manufacturing, and Controls (CMC) Information: Detailed information on the production process, stability, purity, and control of the drug component.
• Non-Clinical and Clinical Data: Include results from preclinical studies, human factors studies, and any clinical trial data supporting efficacy and safety.
• Labeling: Proposed label, instruction for use (IFU), and package insert. Ensure that labeling is not only compliant with FDA regulations but also user-friendly.

Documentation during submission preparation should adhere to the following expectations:

• All sections of the dossier must maintain consistency and clarity to facilitate FDA review.
• Compliance with the Common Technical Document (CTD) format may also be beneficial, especially for drug components.

A comprehensive regulatory submission dossier, meticulously prepared, will expedite the review process and reduce the likelihood of deficiencies during the FDA’s evaluation.

Step 5: Submission and Review Process

Once the dossier is complete, submitting it to the relevant FDA centers marks a significant milestone. Regardless of whether you submit a 510(k), PMA, NDA, or BLA, the submission and subsequent review process is crucial for gaining market approval.

Upon submission, the FDA will initiate a filing review to ensure the application is complete and acceptable for a comprehensive review. Key considerations during the review process include:

• Timelines and Milestones: Ensure adherence to review timelines, which vary based on the submission type. For instance, 510(k) submissions typically undergo a 90-day review process, while PMA submissions can take up to 180 days or more.
• Responding to FDA Inquiries: Be prepared for potential queries or requests for additional data. Having an organized response plan will help streamline this phase.
• Adherence to Good Clinical Practice (GCP): Ensure that clinical data is collected in alignment with GCP standards, and be prepared to demonstrate compliance through an audit if necessary.

Documentation during this step includes:

• Cover letter stating the intent and summaries of the submission.
• Complete and organized file structure for easy navigation by FDA reviewers.

Efforts during the review process will ensure smooth communication and success in gaining approval for the auto-injector.

Step 6: Post-Approval Commitments and Market Surveillance

The final step in the regulatory pathway is the establishment of post-approval commitments. Successfully navigating the review process results in market approval; however, compliance continues long after the product is on the market.

Post-approval actions to consider encompass:

• Post-Market Surveillance: Develop a plan for post-market surveillance and monitoring of safety and effectiveness. This may include a Risk Evaluation and Mitigation Strategy (REMS) if required by regulatory mandates.
• Adverse Event Reporting: Ensure timely reporting of adverse events associated with the auto-injector to the FDA, adhering to 21 CFR Part 803 regulations.
• Labeling Updates: Be vigilant and proactive in updating product labeling based on ongoing evaluations and new safety data.

Documentation requirements in this phase entail:

• Post-market surveillance plan reflecting ongoing monitoring strategies.
• Records of adverse event reports and corrective actions taken.

In conclusion, obtaining regulatory approval for an auto-injector involves a comprehensive understanding of the FDA’s review pathways, pre-submission planning, meticulous dossier preparation, and robust post-approval commitments. By adhering to the outlined steps and maintaining open communication with regulatory authorities, companies can navigate the complicated landscape of FDA combination product consulting with success.